logo
Share SHARE
FONT-SIZE Plus   Neg

General Motors Q1 Profit Slumps - Quick Facts

General Motors Co. (GM, GMM.TO) reported a fall in first-quarter net income attributable to common stockholders to $1.0 billion, or $0.60 per share from $3.2 billion, or $1.77 per share in the year-ago quarter. The company said latest quarter's results include a net loss from special items related to goodwill impairment that reduced net income by $0.6 billion, or $0.33 per share.

On average, 16 analysts polled by Thomson Reuters expected earnings per share of $0.85 for the quarter. Analysts' estimates typically exclude one-time items.

Revenue for the recent quarter totaled $37.8 billion, compared with $36.2 billion in the previous year. Eight analysts estimated revenues of $37.59 billion for the quarter. Adjusted earnings before interest and tax or adjusted-EBIT were $2.2 billion, an increase of $0.2 billion compared with $2.0 billion in the first quarter of 2011.

With the strengthening U.S. economy helping release pent-up demand, GM currently expects full-year 2012 U.S. light vehicle sales to be in the 14.0 million - 14.5 million range. Previously, the company expected sales to fall between 13.5 million - 14.0 million units.

Based on the company's current forecast, GM North America's results for the second and third quarters of 2012 are expected to be comparable to the first quarter of 2012, due to the scheduled downtime at factories that produce full-size trucks.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Coca-Cola Company (KO) reported a profit for the first-quarter of 2017 that declined 20 percent from the prior year. Net revenues declined 11%, reflecting unfavorable impacts from structural changes of 10% and foreign currency of 1%. The company remains on track to deliver its underlying revenue and profit targets for the full year. Eli Lilly and Co. (LLY) reported a loss for the first quarter of 2017 compared to profit in the prior year, primarily hurt by lower operating income, partially offset by higher other income. But, quarterly revenue increased 7 percent, driven by 9 percent pharmaceutical volume growth from Trulicity, Taltz and other new products. Capricor Therapeutics, Inc., a clinical-stage biotechnology company for cardiac and other medical conditions, announced Tuesday positive six-month results from the randomized phase I/II HOPE clinical trial in Duchenne muscular dystrophy or DMD. The HOPE clinical trial was designed to evaluate the safety and exploratory efficacy of CAP-1002.
comments powered by Disqus
Follow RTT